IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes

Alessandro Del Gobbo, Annamaria Morotti, Anna Eleonora Colombo, Valentina Vaira, Giulia Ercoli, Chiara Pesenti, Eleonora Bonaparte, Elena Guerini-Rocco, Andrea Di Cristofori, Marco Locatelli, Alessandro Palleschi, Stefano Ferrero

Research output: Contribution to journalArticle

Abstract

Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3. IMP3 expression was associated with shorter overall survival in the whole series and in subgroups of metastases from non-neuroendocrine pulmonary malignancies and adenocarcinoma metastases. These results indicated that IMP3 is a strong prognostic factor in non-neuroendocrine brain metastases and in particular in patients with adenocarcinoma metastases.

Original languageEnglish
Pages (from-to)2
JournalMedical oncology (Northwood, London, England)
Volume35
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

    Fingerprint

Keywords

  • Adenocarcinoma/mortality
  • Adenocarcinoma of Lung
  • Adult
  • Aged
  • Biomarkers, Tumor/metabolism
  • Brain Neoplasms/metabolism
  • Carcinoma, Non-Small-Cell Lung/mortality
  • Female
  • Humans
  • Immunohistochemistry
  • Lung Neoplasms/mortality
  • Male
  • Middle Aged
  • Neuroendocrine Tumors/metabolism
  • RNA-Binding Proteins/metabolism
  • Survival Analysis

Cite this